LivaNova PLC (NASDAQ:LIVN – Get Free Report) has been given an average rating of “Moderate Buy” by the eleven brokerages that are covering the stock, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $84.1250.
Several analysts have recently weighed in on LIVN shares. Zacks Research downgraded LivaNova from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Weiss Ratings upgraded LivaNova from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, August 18th. KeyCorp lifted their price target on LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, June 22nd. Freedom Capital upgraded LivaNova to a “hold” rating in a research note on Tuesday, June 30th. Finally, Piper Sandler reissued an “overweight” rating and issued a $90.00 price objective (up from $87.00) on shares of LivaNova in a report on Wednesday, September 2nd.
Check Out Our Latest Stock Analysis on LIVN
LivaNova Price Performance
LivaNova (NASDAQ:LIVN – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.17. The company had revenue of $390.59 million during the quarter, compared to the consensus estimate of $380.50 million. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. LivaNova’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.05 earnings per share. As a group, sell-side analysts predict that LivaNova will post 3.77 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, Director Brooke Story sold 2,300 shares of the stock in a transaction on Friday, September 4th. The shares were sold at an average price of $81.42, for a total transaction of $187,266.00. Following the completion of the sale, the director owned 7,488 shares in the company, valued at $609,672.96. This represents a 23.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Francesco Bianchi sold 3,500 shares of the firm’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $78.01, for a total transaction of $273,035.00. Following the transaction, the director directly owned 4,434 shares in the company, valued at $345,896.34. The trade was a 44.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 7,450 shares of company stock worth $591,839 over the last ninety days. Corporate insiders own 0.35% of the company’s stock.
Institutional Investors Weigh In On LivaNova
Hedge funds have recently made changes to their positions in the business. Millennium Management LLC raised its stake in shares of LivaNova by 17.3% during the 4th quarter. Millennium Management LLC now owns 3,484,082 shares of the company’s stock worth $214,376,000 after buying an additional 514,268 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of LivaNova by 1,978.8% in the first quarter. Janus Henderson Group PLC now owns 471,379 shares of the company’s stock valued at $29,961,000 after buying an additional 448,703 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in shares of LivaNova in the first quarter valued at approximately $18,327,000. Rhenman & Partners Asset Management AB grew its holdings in LivaNova by 258.5% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 190,000 shares of the company’s stock worth $11,691,000 after acquiring an additional 137,000 shares during the period. Finally, Boone Capital Management LLC grew its holdings in LivaNova by 72.0% during the fourth quarter. Boone Capital Management LLC now owns 288,895 shares of the company’s stock worth $17,776,000 after acquiring an additional 120,963 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.
LivaNova Company Profile
LivaNova PLC (NASDAQ: LIVN) is a medical device company that develops and manufactures technologies for the treatment of neurological and cardiovascular conditions. The company serves hospitals, physicians and patients in markets around the world, with operations and commercial activities spanning North America, Europe and other international markets.
LivaNova’s Neuromodulation business produces vagus nerve stimulation (VNS) systems marketed under the VNS Therapy brand. These implantable devices are used as an adjunctive treatment for drug-resistant epilepsy and are designed to deliver programmed electrical stimulation to the vagus nerve.
Featured Stories
- Five stocks we like better than LivaNova
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
- AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.
